Allergy D Tablet, Extended Release
NDC Package 0113-9004-22
Package Information
Allergy D (loratadine, pseudoephedrine sulfate) tablets is •do not divide, crush, chew or dissolve the tabletadults and children 12 years and over1 tablet daily with a full glass of water; not more than 1 tablet in 24 hourschildren under 12 years of ageask a doctorconsumers with liver or kidney diseaseask a doctor. This formulation utilizes a tablet, extended release delivery system. Marketed by L. Perrigo Company, this product is identified by NDC 0113-9004 and is authorized under FDA application ANDA075989.
Identification & Billing
- RxCUI: 1117562 - pseudoephedrine sulfate 240 MG / loratadine 10 MG 24HR Extended Release Oral Tablet
- RxCUI: 1117562 - 24 HR loratadine 10 MG / pseudoephedrine sulfate 240 MG Extended Release Oral Tablet
- RxCUI: 1117562 - loratadine 10 MG / pseudoephedrine sulfate 240 MG 24 HR Extended Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0113 - L. Perrigo Company
- 0113-9004 - Allergy D
- 0113-9004-22 - 15 BLISTER PACK in 1 CARTON / 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK
- 0113-9004 - Allergy D
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0113-9004-22 identifies a specific commercial package of 15 blister pack in 1 carton / 1 tablet, extended release in 1 blister pack of Allergy D, a human over the counter drug labeled by L. Perrigo Company. This tablet, extended release is formulated for oral use and contains loratadine; pseudoephedrine sulfate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by L. Perrigo Company on October 03, 2025. The current certification is valid through December 31, 2026.
How is this L. Perrigo Company product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00113900422. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 15 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.